STX64 (667 Coumate, Irosustat), a tricyclic coumarin-based sulfamate that irreversibly inhibits STS activity, has been selected to enter into phase I clinical trials as an STS inhibitor for postmenopausal women with breast cancer [147]. This evidence concerns the gene STS and breast carcinoma.